Relmacabtagene Autoleucel in Patients With LBCL

Summary

To evaluate the efficacy and safety of Relmacabtagene autoleucel for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) in real-world

Conditions

• Large B-cell Lymphoma

Interventions

BIOLOGICAL

Relmacabtagene Autoleucel

A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

Sponsors & Collaborators

• Shanghai Ming Ju Biotechnology Co., Ltd.

  lead INDUSTRY

Principal Investigators

• Weili Zhao, PhD · Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

• Huiqiang Huang, PhD · Sun Yat-sen University

• Liang Huang, PhD · Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

• Ping Li · Shanghai Tongji Hospital, Tongji University School of Medicine

• Heng Mei · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

• Hongmei Jing · Peking University Third Hospital

• Wenbin Qian · Second Affiliated Hospital, School of Medicine, Zhejiang University

• Depei Wu · The First Affiliated Hospital of Soochow University

• Ying Lu · Ningbo University People's Hospital

• Huilai Zhang · Tianjin Cancer Hospital

• Qingyuan Zhang · Harbin Medical University Tumor Hospital

• Dehui Zou · Hematology Hospital, Chinese Academy of Medical Sciences

• Yao Liu · Chongqing University Cancer Hospital

• Jianqiu Wu · Jiangsu Provincial Tumor Hospital

• Yajun Li · Hunan Cancer Hospital

• Ru Feng · Southern Medical University, China

• Yuhua Li · Nanfang Hospital, Southern Medical University

• Zhifeng Li · The First Hospital of Xiamen University

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-12-28

Primary Completion

2024-12-31

Completion

2024-12-31

Countries

• China

Study Locations